Segall Bryant & Hamill LLC Lowers Holdings in Glaukos Corporation (NYSE:GKOS)

Segall Bryant & Hamill LLC lowered its holdings in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 2.7% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 101,679 shares of the medical instruments supplier's stock after selling 2,870 shares during the period. Segall Bryant & Hamill LLC owned about 0.18% of Glaukos worth $10,007,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of GKOS. Bessemer Group Inc. grew its position in shares of Glaukos by 133.9% in the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock valued at $27,000 after buying an additional 158 shares during the last quarter. Harbor Capital Advisors Inc. grew its position in shares of Glaukos by 59.5% in the 1st quarter. Harbor Capital Advisors Inc. now owns 39,132 shares of the medical instruments supplier's stock valued at $3,851,000 after buying an additional 14,593 shares during the last quarter. Teacher Retirement System of Texas grew its position in shares of Glaukos by 606.7% in the 4th quarter. Teacher Retirement System of Texas now owns 20,247 shares of the medical instruments supplier's stock valued at $3,036,000 after buying an additional 17,382 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Glaukos by 35.2% in the 1st quarter. SG Americas Securities LLC now owns 4,924 shares of the medical instruments supplier's stock valued at $485,000 after buying an additional 1,283 shares during the last quarter. Finally, Comerica Bank grew its position in shares of Glaukos by 664.5% in the 4th quarter. Comerica Bank now owns 151,538 shares of the medical instruments supplier's stock valued at $22,722,000 after buying an additional 131,715 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Glaukos Trading Down 0.7%

NYSE GKOS traded down $0.73 during trading on Monday, hitting $96.97. The stock had a trading volume of 618,759 shares, compared to its average volume of 747,887. Glaukos Corporation has a one year low of $77.10 and a one year high of $163.71. The stock has a 50 day simple moving average of $98.28 and a 200 day simple moving average of $112.14. The stock has a market capitalization of $5.54 billion, a price-to-earnings ratio of -40.92 and a beta of 0.82. The company has a debt-to-equity ratio of 0.09, a quick ratio of 5.62 and a current ratio of 6.49.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.11. Glaukos had a negative net margin of 31.40% and a negative return on equity of 10.66%. The firm had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. During the same quarter in the previous year, the firm posted ($0.70) earnings per share. The company's revenue was up 24.6% on a year-over-year basis. Sell-side analysts predict that Glaukos Corporation will post -1.08 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on GKOS. Piper Sandler dropped their price target on Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 15th. Morgan Stanley reduced their price objective on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Stephens lowered their price target on Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Truist Financial restated a "buy" rating and issued a $135.00 target price (down previously from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. Finally, BTIG Research reissued a "buy" rating on shares of Glaukos in a research note on Monday, July 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat.com, Glaukos has a consensus rating of "Moderate Buy" and a consensus target price of $134.67.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.